The next generation of novel therapies for the management of relapsed multiple myeloma

Wilson Gonsalves, Paolo Milani, Daniel Derudas, Francis K. Buadi

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The advent of various novel therapies such as immunomodulators and proteasome inhibitors has transformed the treatment paradigm for patients with multiple myeloma (MM). As a result, the overall survival has improved dramatically over the last decade. Despite these advances, MM remains mostly incurable and most patients experience disease relapse after enjoying a period of disease control or remission. Fortunately, the scientific community continues to make strides in developing 'next-generation' therapies for the management of patients with relapsed MM. This review will summarize the efficacy of some of the newest therapeutic agents available for the treatment of patients with relapsed MM after their upfront treatment with the original novel agents such as thalidomide, lenalidomide and bortezomib.

Original languageEnglish (US)
Pages (from-to)63-75
Number of pages13
JournalFuture Oncology
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Multiple Myeloma
Therapeutics
Proteasome Inhibitors
Thalidomide
Immunologic Factors
Recurrence
Survival

Keywords

  • multiple myeloma
  • novel agents
  • relapse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The next generation of novel therapies for the management of relapsed multiple myeloma. / Gonsalves, Wilson; Milani, Paolo; Derudas, Daniel; Buadi, Francis K.

In: Future Oncology, Vol. 13, No. 1, 01.01.2017, p. 63-75.

Research output: Contribution to journalReview article

Gonsalves, Wilson ; Milani, Paolo ; Derudas, Daniel ; Buadi, Francis K. / The next generation of novel therapies for the management of relapsed multiple myeloma. In: Future Oncology. 2017 ; Vol. 13, No. 1. pp. 63-75.
@article{aebc3b2348f94e8aa2e4cc6444cb47ab,
title = "The next generation of novel therapies for the management of relapsed multiple myeloma",
abstract = "The advent of various novel therapies such as immunomodulators and proteasome inhibitors has transformed the treatment paradigm for patients with multiple myeloma (MM). As a result, the overall survival has improved dramatically over the last decade. Despite these advances, MM remains mostly incurable and most patients experience disease relapse after enjoying a period of disease control or remission. Fortunately, the scientific community continues to make strides in developing 'next-generation' therapies for the management of patients with relapsed MM. This review will summarize the efficacy of some of the newest therapeutic agents available for the treatment of patients with relapsed MM after their upfront treatment with the original novel agents such as thalidomide, lenalidomide and bortezomib.",
keywords = "multiple myeloma, novel agents, relapse",
author = "Wilson Gonsalves and Paolo Milani and Daniel Derudas and Buadi, {Francis K.}",
year = "2017",
month = "1",
day = "1",
doi = "10.2217/fon-2016-0200",
language = "English (US)",
volume = "13",
pages = "63--75",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - The next generation of novel therapies for the management of relapsed multiple myeloma

AU - Gonsalves, Wilson

AU - Milani, Paolo

AU - Derudas, Daniel

AU - Buadi, Francis K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The advent of various novel therapies such as immunomodulators and proteasome inhibitors has transformed the treatment paradigm for patients with multiple myeloma (MM). As a result, the overall survival has improved dramatically over the last decade. Despite these advances, MM remains mostly incurable and most patients experience disease relapse after enjoying a period of disease control or remission. Fortunately, the scientific community continues to make strides in developing 'next-generation' therapies for the management of patients with relapsed MM. This review will summarize the efficacy of some of the newest therapeutic agents available for the treatment of patients with relapsed MM after their upfront treatment with the original novel agents such as thalidomide, lenalidomide and bortezomib.

AB - The advent of various novel therapies such as immunomodulators and proteasome inhibitors has transformed the treatment paradigm for patients with multiple myeloma (MM). As a result, the overall survival has improved dramatically over the last decade. Despite these advances, MM remains mostly incurable and most patients experience disease relapse after enjoying a period of disease control or remission. Fortunately, the scientific community continues to make strides in developing 'next-generation' therapies for the management of patients with relapsed MM. This review will summarize the efficacy of some of the newest therapeutic agents available for the treatment of patients with relapsed MM after their upfront treatment with the original novel agents such as thalidomide, lenalidomide and bortezomib.

KW - multiple myeloma

KW - novel agents

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=85002245091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002245091&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0200

DO - 10.2217/fon-2016-0200

M3 - Review article

C2 - 27513456

AN - SCOPUS:85002245091

VL - 13

SP - 63

EP - 75

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 1

ER -